Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/34826| Title: | PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. | Austin Authors: | Albert, Nathalie L;Galldiks, Norbert;Ellingson, Benjamin M;van den Bent, Martin J;Chang, Susan M;Cicone, Francesco;de Groot, John;Koh, Eng-Siew;Law, Ian;Le Rhun, Emilie;Mair, Maximilian J;Minniti, Giuseppe;Rudà, Roberta;Scott, Andrew M ;Short, Susan C;Smits, Marion;Suchorska, Bogdana;Tolboom, Nelleke;Traub-Weidinger, Tatjana;Tonn, Joerg-Christian;Verger, Antoine;Weller, Michael;Wen, Patrick Y;Preusser, Matthias | Affiliation: | Department of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany. Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany; Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany. UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. The Brain Tumour Center at the Erasmus MC Cancer Institute, Rotterdam, Netherlands. Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA. Nuclear Medicine Unit, Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy. Department of Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centre, Liverpool, NSW, Australia; South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia. Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, Denmark. Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland; Department of Neurology, University Hospital Zurich, Zurich, Switzerland. Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy; IRCCS Neuromed, Pozzilli IS, Italy. Division of Neuro-Oncology, Department of Neuroscience, University of Turin and City of Health and Science of Turin, Turin, Italy. Molecular Imaging and Therapy Leeds Institute of Medical Research at St James's, The University of Leeds, Leeds, UK. Department of Radiology & Nuclear Medicine, Erasmus MC-University Medical Centre Rotterdam, Rotterdam, Netherlands; Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, Netherlands; Medical Delta, Delft, Netherlands. Department of Neurosurgery, Heidelberg University Hospital, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany. Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, Netherlands. Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. Department of Neurosurgery, LMU Hospital, LMU Munich, Munich, Germany. Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU Nancy and IADI INSERM UMR 1254, Universitè de Lorraine, Nancy, France. Department of Neurology, University Hospital Zurich, Zurich, Switzerland; Department of Neurology, University of Zurich, Zurich, Switzerland. Center For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. |
Issue Date: | Jan-2024 | Publication information: | The Lancet. Oncology 2024-01; 25(1) | Abstract: | Response Assessment in Neuro-Oncology (RANO) response criteria have been established and were updated in 2023 for MRI-based response evaluation of diffuse gliomas in clinical trials. In addition, PET-based imaging with amino acid tracers is increasingly considered for disease monitoring in both clinical practice and clinical trials. So far, a standardised framework defining timepoints for baseline and follow-up investigations and response evaluation criteria for PET imaging of diffuse gliomas has not been established. Therefore, in this Policy Review, we propose a set of criteria for response assessment based on amino acid PET imaging in clinical trials enrolling participants with diffuse gliomas as defined in the 2021 WHO classification of tumours of the central nervous system. These proposed PET RANO criteria provide a conceptual framework that facilitates the structured implementation of PET imaging into clinical research and, ultimately, clinical routine. To this end, the PET RANO 1.0 criteria are intended to encourage specific investigations of amino acid PET imaging of gliomas. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/34826 | DOI: | 10.1016/S1470-2045(23)00525-9 | ORCID: | Journal: | The Lancet. Oncology | Start page: | e29 | End page: | e41 | PubMed URL: | 38181810 | ISSN: | 1474-5488 | Type: | Journal Article | Subjects: | Glioma/diagnostic imaging Glioma/therapy |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.